European Meeting on HIV & Hepatitis 2018

Long acting HIV drugs for treatment: what are the data? | Anton Pozniak, MD, FRCP

Video

HIV

Viral Hepatitis and Liver Disease

Long acting HIV drugs for prevention: what are the data? | Pep Coll, MD

Video

HIV

Viral Hepatitis and Liver Disease

A new wild-type HIV in the era of transmitted drug resistance | Kristof Theys, PhD

Video

HIV

Viral Hepatitis and Liver Disease

The current status of PrEP in Europe | Pep Coll, MD

Video

HIV

Viral Hepatitis and Liver Disease

Influence of resistance in the future | Richard Harrigan, MD

Video

HIV

Viral Hepatitis and Liver Disease

Clinical trial data 3 vs 2 drug regimens | Andrea De Luca, MD

Video

HIV

Viral Hepatitis and Liver Disease

Implications for clinical practice | Jonathan Schapiro, MD

Video

HIV

Viral Hepatitis and Liver Disease

New technologies reaching the clinic | Martin Däumer, MSc

Video

HIV

Viral Hepatitis and Liver Disease

Novel simplified bioinformatics for NGS data analysis | Marc Noguera-Julian, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Management of hepatitis C therapy failures - virological perspective | Francesca Ceccherini– Silberstein, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Management of hepatitis C therapy failures - clinical perspective | Sanjay Bhagani, BSc FRCP

Video

HIV

Viral Hepatitis and Liver Disease

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

Video

HIV

Viral Hepatitis and Liver Disease

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

Video

HIV

Viral Hepatitis and Liver Disease

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

Video

HIV

Viral Hepatitis and Liver Disease

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

Video

HIV

Viral Hepatitis and Liver Disease

Reduced drug regimens | Andrea De Luca, MD

Video

HIV

Viral Hepatitis and Liver Disease

What is the place of the monoclonal antibodies in the clinic | Julià Blanco, PhD

Video

HIV

Viral Hepatitis and Liver Disease

European Meeting on HIV & Hepatitis 2018

The HIV epidemic in CEE countries | Oana Săndulescu, MD, PhD

How would the epidemic evolve in the future | David van de Vijver, PHARMD, PHD

Improving drug delivery: what are the new technologies? | Saye Khoo, MD, PhD

Long acting HIV drugs for treatment: what are the data? | Anton Pozniak, MD, FRCP

Long acting HIV drugs for prevention: what are the data? | Pep Coll, MD

A new wild-type HIV in the era of transmitted drug resistance | Kristof Theys, PhD

The current status of PrEP in Europe | Pep Coll, MD

Influence of resistance in the future | Richard Harrigan, MD

Clinical trial data 3 vs 2 drug regimens | Andrea De Luca, MD

Implications for clinical practice | Jonathan Schapiro, MD

New technologies reaching the clinic | Martin Däumer, MSc

Novel simplified bioinformatics for NGS data analysis | Marc Noguera-Julian, PhD

Management of hepatitis C therapy failures - virological perspective | Francesca Ceccherini– Silberstein, PhD

Management of hepatitis C therapy failures - clinical perspective | Sanjay Bhagani, BSc FRCP

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

What’s in the pipeline? Presentations by scientists from the industry | Kathleen Squires, MD

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

What’s in the pipeline? Presentations by scientists from the industry | Jean-Marc Steens, MD

Reduced drug regimens | Andrea De Luca, MD

What is the place of the monoclonal antibodies in the clinic | Julià Blanco, PhD

Prospects for cure | Annemarie Wensing, MD, PhD